Sulphonylurea Failure in Type 2 Diabetes: Treatment with a Basal Insulin Supplement
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Many diabetic patients continue to have hyperglycaemia on maximal sulphonylurea therapy. Five different therapeutic options, with the prime aim of achieving normal fasting plasma glucose concentrations, have been compared in 15 asymptomatic, sulphonylurea‐treated type 2 diabetic patients in a randomized crossover study of 8‐week periods. In 24 h metabolic profiles the overnight mean (±1SD) basal plasma glucose level on sulphonylurea therapy was 8.9±4.2 mmol/l. This was slightly improved with added metformin therapy (7.3±4.3 mmol/l, p=0.013), but reduced to normal by added ultralente insulin (5.2±3.2 mmol/l, p<0.001), ultralente insulin alone (5.1±1.6 mmol/l, p=0.005) or by ultralente and soluble insulin (4.7±1.4 mmol/l, p=0.003). The mean glycosylated haemoglobin concentration was reduced significantly only by the treatments which included insulin. None of the patients had severe or incapacitating hypoglycaemia and only when on additional soluble insulin did patients show a significant gain in weight. Combining sulphonylurea therapy with ultralente insulin did not significantly improve overall glucose control over treatment with ultralente alone, although the insulin dose required to restore fasting normoglycaemia was significantly lower (median (interquartile range), 25 (12–41) versus 40 (27–80) U/day, p=0.001). In type 2 diabetic patients who continue to have fasting hyperglycaemia on maximal sulphonylurea therapy, fasting normoglycaemia can be achieved easily, without minimal changes in diet or lifestyle, by means of a basal insulin supplement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE BASAL PLASMA GLUCOSE: A SIMPLE RELEVANT INDEX OF MATURITY‐ONSET DIABETES
HOLMAN, R. R., & TURNER, R. C. (1981) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1981.tb00196.x · Cited by 64
Self-citationControl of maturity-onset diabetes by monitoring fasting blood glucose and body weight
Howe-Davies, S., Simpson, R. W., & Turner, R. C. (1980) · Diabetes Care · doi:10.2337/diacare.3.5.607 · Cited by 49
Self-citation
Cited by
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Bailey, C. J. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.755 · Cited by 593
Wright, A., Burden, A. C. F., Paisey, R. B., Cull, C. A., Holman, R. R., & for the U.K. Prospective Diabetes Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.2.330 · Cited by 556
Self-citationOates, J. A., Wood, A. J. J., & Gerich, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911023211805 · Cited by 480
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Metadata
- Authors
- Holman, R. R., Steemson, J., & Turner, R. C.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 1987-09-10
- Volume
- 4
- Issue
- 5
- Pages
- 457-462
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2066042609
- Cited by
- 73
- References
- 2
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sulphonylurea Failure in Type 2 Diabetes: Treatment with a Basal Insulin Supplement. https://app.cochat.ai/papers/10.1111/j.1464-5491.1987.tb00909.x
- The paper
- Holman, R. R., Steemson, J., & Turner, R. C. (1987). Sulphonylurea Failure in Type 2 Diabetes: Treatment with a Basal Insulin Supplement. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.1987.tb00909.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.